Aim Immunotech Inc (AIM) - News Archive

AIM ImmunoTech, a renowned biopharmaceutical company, continues to advance its clinical development pipeline, displaying remarkable progress across various Ampligen clinical programs. This article will outline the recen...

In a stride towards revolutionizing pancreatic cancer treatment, AIM ImmunoTech has recently administered its first subject in the Netherlands for a Phase 1b/2 study evaluating the combination of Ampligen (rintatolimod)...

AIM ImmunoTech, a biotechnology company focused on the research and development of therapeutic treatments for multiple types of cancers, recently announced a milestone in its latest clinical trial. The company has accom...

Pancreatic cancer, notorious for its aggressive nature and reduced survivorship index, has remained an area of considerable concern in the domain of clinical medicine. The medical industry has fervently been scouting fo...

AIM ImmunoTech, a leading biopharmaceutical company, has announced the publication of exciting data from a Phase 1 study of Ampligen at the Roswell Park Comprehensive Cancer Center. The study evaluated the use of Amplig...

AIM ImmunoTech, a leading biopharmaceutical company, has announced its collaboration with Azenova, a renowned business development consulting firm. The partnership aims to accelerate the partnering, development, and com...